Studies Suggest Controversial Multiple Sclerosis Drug Is Safe
HealthDay via Yahoo! News Wed, 01 Mar 2006 2:02 PM PST
WEDNESDAY, March 1 (HealthDay News) -- New data on a controversial multiple sclerosis drug pulled from the market a year ago found that the drug actually appears to be effective and safe, at least for the short term.

TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Business Wire via Yahoo! Finance Wed, 01 Mar 2006 2:01 PM PST CAMBRIDGE, Mass. and DUBLIN, Ireland----March 1, 2006--Biogen Idec and Elan Corporation, plc announced today that two-year results from the two Phase III clinical trials evaluating TYSABRI® for patients with relapsing forms of multiple sclerosis , as well as data from the comprehensive safety evaluation of the product were published for the first time in this week's issue of The New England

Studies Suggest Controversial Multiple Sclerosis Drug Is Safe Health Scout Wed, 01 Mar 2006 4:48 PM PST But some risk exists so more evaluation is needed, experts say.

Studies Find Withdrawn MS Drug Effective AP via Yahoo! News Wed, 01 Mar 2006 7:24 PM PST A promising multiple sclerosis drug that was suspended from the market because three people developed a rare brain disease now appears relatively safe and quite effective, three studies found.

Tysabri effective for MS but carries some risk Reuters via Yahoo! News Wed, 01 Mar 2006 6:15 PM PST Tysabri, a drug made by Biogen Idec and Elan Pharmaceuticals, significantly reduces the rate of disease progression in patients with relapsing multiple sclerosis (MS), according to the results of two trials reported in this week's New England Journal of Medicine.

MS patients want return of drug that has serious risk Chicago Sun-Times Thu, 02 Mar 2006 2:38 AM PST A $24,000-a-year drug called Tysabri looks like the best new multiple sclerosis treatment in years. Tysabri reduces the rate of MS relapses by about two-thirds, and might prove beneficial for rheumatoid arthritis and Crohn's disease.

MS Drug: No More Rare Disease Cases WebMD Wed, 01 Mar 2006 4:53 PM PST Researchers have found no new cases of a rare disease in patients who took the multiple sclerosis drug Tysabri before the drug's suspension last year.

Health News | Home EARTHtimes.org Thu, 02 Mar 2006 7:40 AM PST Tysabri, a drug generically known as natalizumab that was pulled off the market after three users developed a serious brain condition, decreases the rate of disease progression in those suffering from a relapse of multiple sclerosis (MS), three trial studies have found.

Evaluation of Patients Treated With Natalizumab Finds No New Cases of Progressive Multifocal Leukoencephalopathy National Institutes of Health Thu, 02 Mar 2006 5:54 AM PST An independent clinical and laboratory study of more than 3000 people treated with the drug natalizumab (Tysabri ® ) for multiple sclerosis (MS), Crohn’s disease, and rheumatoid arthritis has found no evidence of new cases of the often-fatal disorder called progressive multifocal leukoencephalopathy (PML). The laboratory component of the study was coordinated by the National Institute of

MS Research Into Reparative Cells Offers New Avenue for Fighting Disease
Newswise Wed, 01 Mar 2006 3:28 PM PST
Plaques that form around the nerve cells of people with multiple sclerosis are apparently what disable people with the disease. But partly developed reparative cells within the plaques provide hope for a treatment.